Previous 10 | Next 10 |
BTIG analyst Robert Hazlett puts forth a bullish case for shares of MannKind Corp. (MNKD), doubling his price target to $8.He says that a collaboration with United Therapeutics (UTHR) for Tyvaso DPI in pulmonary arterial hypertension has "transformational potential."Tyvaso DPI is a next-gener...
United Therapeutics (UTHR): Q4 Non-GAAP EPS of $3.31 misses by $0.20; GAAP EPS of $2.19 misses by $0.96.Revenue of $384.9M (+23.7% Y/Y) beats by $22.86M.Press Release For further details see: United Therapeutics EPS misses by $0.20, beats on revenue
United Therapeutics Corporation Reports Fourth Quarter And Full Year 2020 Financial Results PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its fina...
United Therapeutics (NASDAQ:UTHR) is scheduled to announce Q4 earnings results on Wednesday, February 24th, before market open.The consensus EPS Estimate is $3.46 (+76.5% Y/Y) and the consensus Revenue Estimate is $361.07M (+16.1% Y/Y).Over the last 2 years, UTHR has beaten EPS estimates 88% ...
The IPO market is as hot as it has been since 1999. I was curious about the performance of 1999's IPO class of stocks. So, I explored the outcomes of 73 IPOs from 1999 to see what happened to them over the past 22 years. For further details see: The Odds Of Winning The I...
United Therapeutics Corporation To Report Fourth Quarter And Full Year 2020 Financial Results Before The Market Opens On Wednesday, February 24, 2021 PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 17, 2021 /PRNewswire/ -- United T...
United Therapeutics Announces Commercial Launch Of The Remunity® Pump For Remodulin® PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today ...
UTHR is progressing with its next-generation dry powder formulation, Tyvaso DPI, towards the market. It plans to file an NDA under priority review in April 2021. Tyvaso DPI and PhaseBio's Pemziviptadil are very different products. For further details see: United Therapeu...
I won't say, "I told you so." In fact, I didn't tell you so -- not outright at least. But in discussing Proto Labs ' (NYSE: PRLB) remarkable 12.3% jump in stock price yesterday, I think I at least implied that there wasn't any good reason for it and that investors were lumping in Pr...
United Therapeutics (UTHR) has announced that its Tyvaso DPI (inhaled treprostinil) met its primary objective of demonstrating safety and tolerability in patients with pulmonary arterial hypertension (“PAH”) transitioning from Tyvaso (treprostinil) inhalation solution.In a separ...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...